https://doi.org/10.4081/ejh.2020.3166

LncRNA GClnc1 may contribute to the progression of ovarian cancer by regulating p53 signaling pathway

Vol. 64 No. 4 (2020)
Submitted: 23 July 2020
Accepted: 4 September 2020
Published: 10 November 2020
lncRNA, GClnc1, p53, ovarian cancer, target therapy
Abstract Views: 622
PDF: 514
HTML: 7
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Hu Li
Department of Gynecology; Cancer Institute of Panyu Central Hospital, Guangzhou, China.
Zheng Zeng
Department of Gynecology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiang Yang
Department of Gynecology, Panyu Central Hospital, Guangzhou, China.
Ye Chen
Department of Gynecology, Panyu Central Hospital, Guangzhou, China.
Lei He
helei33@mail.sysu.edu.cn
https://orcid.org/0000-0003-2573-4302
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Ting Wan
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Ovarian cancer (OC) is one of the most prevalent and deadly types of gynecological malignancy. Since current treatments are not effective against OC, it is imperative to develop novel potential therapeutic targets for managing OC. In this study, we aimed to uncover the underlying molecular mechanism of long non-coding RNA (lncRNA) GClnc1 related to p53 signaling pathway in OC. The expression of lncRNA H19 GClnc1 was markedly higher in OC samples than the related normal tissues. Next, we found that lncRNA GClnc1 inhibited p53. In addition, the lncRNA GClnc1 overexpression promoted the cell proliferation and migration in vitro. Subsequently, p53 silencing obligated the effect of lncRNA GCln1 knock down on cell proliferation and migration. To sum up, LncRNA GClnc1 contributes to the progression of OC by regulating p53 signaling pathway. Meanwhile, our findings also suggested that lncRNA GClnc1 may serve as a novel therapeutic target for OC patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Li, H., Zeng, Z., Yang, X., Chen, Y., He, L., & Wan, T. (2020). LncRNA GClnc1 may contribute to the progression of ovarian cancer by regulating p53 signaling pathway. European Journal of Histochemistry, 64(4). https://doi.org/10.4081/ejh.2020.3166

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

<< < 4 5 6 7 8 9 10 11 12 13 > >> 

You may also start an advanced similarity search for this article.